Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma

Bone Marrow Transplantation

Volumn 41, Issue 7, 2008, Pages 597-604

  Duarte, R F ^a   Schmitz, N ^b   Servitje, O ^c   Sureda, A ^d  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ANTIBODY; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CUTANEOUS T CELL LYMPHOMA; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; MYCOSIS FUNGOIDES; PATIENT SAFETY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SEZARY SYNDROME; SURVIVAL TIME; TOTAL SKIN ELECTRON THERAPY; TREATMENT RESPONSE; WHOLE BODY RADIATION;

GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; REMISSION INDUCTION; SKIN NEOPLASMS; TRANSPLANTATION, HOMOLOGOUS;

EID: 42149127587     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705968     Document Type: Review

References (43)

1. Weinstock MA, Horm JW. Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42-46.
2. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999; 89: 1240-1244.
3. Willemze R, Jaffe ES, Burg G Cerroni L, Berti E, Swerdlow SH et al WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
4. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary sindrome. Blood 1996; 88: 2385-2409.
5. Bunn Jr PA, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep 1979; 63: 725-728.
6. Kuzel TM, Roenig Jr HH, Rosten ST. Mycosjs fungoides and the Sezary syndrome: A review of pathogenesis, diagnosis, and, therapy. J Clin Oncol 1991; 9: 1298-1313.
7. Van Doorn R, van Haselen CW, van Voorst Vader PG, Geerts ML, Heule F, de Rie M et al. Mycosis fungoides: Disease evolution and pronosis of 309 Dutch patients. Arch Dermatol 2000, 136: 504-510.
8. Siegel RS, Pandolfino T, Guitart J, Rosen ST, Kuzel TM. Primary cutaneous. T-cell lymphoma: Review and current concepts. J Clin Oncol 2000; 115: 798-812.
9. Whittaker SJ, Marsden JR, Spittle M, Russell-Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma. Groups guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095-1107.
10. Willemze R. Prognostic factors in cutaneous T-cell lymphoma. Haematotogica Reports 2006; 2: 89-92.
11. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R et al. Revisions to the staging and classification of mycosis fangoides and Sézary syndrome: A proposal of the International Society for Cutaneous. Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
12. Pichardo DA, Querfeld C, Guitart J, Kuzel TM, Rosen ST. Cutaneous T-cell lymphoma: A paradigm for biological therapies. Leuk Lymphoma 2004; 45: 1755-1765.
13. Scarisbrick JJ, Staging and management of cutaneous T-cell lymphoma. Clin Exp Dermatol 2006; 31: 181-186.
14. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L et al. EORTC consensus recommendations for the treatmeut mycosis fungoides/Sézary-syndrome. Eur J Cancer 2006; 42: 1014-1030.
15. Whittaker SJ, Foss FM. Efficacy and tolerability.of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007; 33: 146-160.
16. Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1475-1483.
17. Schmitz N. Stem cell transplantation in adults: Lymphoma. In: Apperley JF, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds). Haematopoietic Stem Cell Transplantation - ESHIEBMT Handbook, 2nd edn, chapter 16.3, Forum Service Editore: Genoa. Italy, 2004, pp. 268-275.
18. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, Demirer T, Dini G, Linsele H et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: Definitions and current practice in Europe, Bone Morrow Transplant 2006; 37 439-449.
19. Chen YC, Wang CH, Huang SC. Lee FF, Lin DT, Shen MC et al. Autologous bone marrow transplantation after supralethal dose of total body irradiation in a case of mycosis fungoides. Taiwan Yi Xue Hui Za Zhi 1986; 85: 304-314.
20. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S et al Autologous bone marrow, transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991; 7; 133-137.
21. Sterling JC, Marcus R, Burrows NP, Roberts SO. Erythrodermic mycosis fungoides treated with total body irradiation and autologous bone marrow transplantation. Clin Exper Dermatol 1995; 20: 73-75.
22. Ferra C, Servitie C, Petriz L, Estrach T, Marti R, Limón A et al Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 1999; 140: 1188-1189.
23. Gabriel IH, Olavarria E, Jones RR, Whittaker SJ, Chaidos A, Apperley JF. Graft versus lymphoma effect after early relapse following reduced-intensity sibling stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplant 2007; 40: 401-403.
24. Olavarria E, Child F, Woolford A, Whittaker SJ, Davis JG, McDonald C et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 2001; 114: 624-631.
25. Russell-Jones R, Child F, Olavarria E, Whittaker SJ, Spittle M, Apperley JF. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: Predictors of disease-free survival. Ann NY Acad Sci 2001; 941: 147-154.
26. Ingen-Housz-Oro S. Bachéeles H. Verola O, Lebbé C, Marolleau JP, Hennequin C et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant 2004; 33: 629-634.
27. Koeppel MC, Stoppa AM, Resbeut M, Blaise D, Coignet M, Coulier L et al. Mycosis fungoides and allogeneic bone marrow transplantation. Acta Derm Venereol 1994; 74: 331-332.
28. Burt RK, Guitart J, Traynor A, Link C, Rosen ST, Pandolfino T et al Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: Evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000; 25: 111-113.
29. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A et al Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma, Arch Dermatol 2002; 138: 1359-1365.
30. Massod N, Russell KJ, Olerud JE, Sabath DE, Sale GE, Doney KC et al Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002; 47: 140-145.
31. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sézary syndrome alter bone marrow transplantation from a matched unrelated donor. Biol Blood Marrow Transplant 1999; 5: 400-404.
32. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J et al. Durable clinical. cytogenetic, and molecular remissions after' allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and Mycosis Fungoides. J Clin Oncol 2005; 23 6163-6171.
33. Carrié E, Buzyn A, Fraigat S, Hermine O; Bodemer C. Mycosis fongoide transformé chez un enfant: Traitement par transplantation médullaire allogénique avec effect graft-versus-lymphoma'. Ann Dermatol Venereol 2007; 134: 471-476.
34. Soligo D, Ibatici A, Berti E, Morando P. Longhi E, Venegoni L et al Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen, Bone Marrow Transplant 2003; 31: 663-666.
35. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantaton. Bone Marrow-Transplant 2004; 34: 521-525.
36. Onida F, Saporiti G, Berti E, Della Volpe A, Annaloro C, Usardi P et al. Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in Advanced mycosis fungoides and Sézary syndrome. Bone Marrow Transplant 2007; 39(Suppl. 1): S40 (abstract O360).
37. Nishio M, Sawada K, Koizumi K, Tarumi T, Takano H, Endo T et al. Recurrence with histological transformation 40 days after autologous peripheral blood stem cell transplantation (APBSCT) for cutaneous CD30-negative large T cell lymphoma. Bone Marrow Transplant 1998; 22: 1211-1214.
38. Nishio M, Koizumi K, Endo T, Takashima H, Haseyama Y, Fujimoto K et al. Effective high-dose chemotherapy combined with CD34+selected autolopous peripheral blood stem cell transplantation in a patient with cutaneous CD30-negative large T-cell lymphoma. Bone Marrow Transplant 2000 25: 1315-1317.
39. Koizumi K, Sawada K, Nishio, M, Katagiri E, Fukae J, Fukada Y et al Effective high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in a patient with the aggressive form of cytophagic histiocytic panniculitis. Bone Marrow Transplant 1997; 20: 171-173.
40. Hashimoto H, Sawada K, Koizumi K, Nishio N, Endo T, Takashima T et al Effective CD34+ -selected autologous peripheral blood stem cell transplantation in a patient with subcutaneous panniculitic T cell lymphoma (SPTCL) transformed into leukemia. Bóne Marrow Transplant 1999; 24: 1369-1371.
41. Haycox CL, Back AL, Raugi GJ,.Piepkorn M. Subcutaneous T-cell lymphoma treated with systemic chemotherapy, autologous stem cell support, and limb amputation. J Am Acad Dermatol 1997; 37: 832-835.
42. Fijnheer R, Sanders CJG, Canniga MR, de Weger RA, Verdonck LF. Complete remission of a radiochemotherapy-resistant cutaneous, T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2003; 32: 345-347.
43. Pérez-Persona E, Mateos-Mazón JJ, López-Villar O, Arcos MJ, Encinas C, Graciani IF et al. Complete remission of subcutaneous panniculitic T-cell lymphoma alter allogeneic transplantation, Bone Marrow Transplant 2006; 38: 821-822.